Tenax Therapeutics (TENX) is in a very good position as far as its drug development plan goes for its drug levosimendan. That's because it is already in the process of running the ongoing phase 3 ...
Alector, Inc. is a pre-revenue biotech reset after Latozinemab’s Phase 3 failure, now trading at a deep discount. Nivisnebart, targeting Alzheimer’s, is ALEC’s next major catalyst; interim Phase 2 ...
Novartis’ phase 3 trial of serelaxin in acute heart failure has missed its primary endpoint. The Swiss pharma saw the 6,600-patient trial as a way to bounce back from FDA’s 2014 rejection, but instead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback